StoxGlaxosmithkline Pharmaceuticals vs Global Health: share price & financials comparison
NSE: GLAXO vs MEDANTA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glaxosmithkline Pharmaceuticals vs Global Health at a glance
Glaxosmithkline Pharmaceuticals (GLAXO) has a market capitalisation of ₹45,277 Cr, against ₹39,065 Cr for Global Health (MEDANTA). Over the past year Global Health has returned +16.4%, compared with +0.5% for Glaxosmithkline Pharmaceuticals. On valuation, Glaxosmithkline Pharmaceuticals trades at a lower P/E of 87.9 versus 98.2. Glaxosmithkline Pharmaceuticals earns a higher return on equity (27.4% vs 9.2%). Glaxosmithkline Pharmaceuticals comes out ahead on size, valuation and profitability. Global Health comes out ahead on growth, momentum and technicals. Across the scored metrics below, Glaxosmithkline Pharmaceuticals leads on 7 and Global Health on 7. On StoxGud's 10-point checklist, Glaxosmithkline Pharmaceuticals scores 7/10 and Global Health scores 6/10.
| Metric | Glaxosmithkline Pharmaceuticals | Global Health |
|---|---|---|
| Size | ||
| Market cap | ₹45,277 Cr | ₹39,065 Cr |
| Revenue (latest FY) | ₹3,822 Cr | ₹4,410 Cr |
| Net profit (latest FY) | ₹1,036 Cr | ₹556 Cr |
| Valuation | ||
| P/E | 87.9 | 98.2 |
| P/B | 24.07 | 9.04 |
| Dividend yield | 1.58% | 0.03% |
| Profitability | ||
| Return on equity | 27.4% | 9.2% |
| Net profit margin | 12.4% | 7.9% |
| Operating margin | 34.1% | 22.1% |
| Growth | ||
| Revenue growth (YoY) | +20.8% | +33.6% |
| Net profit growth (YoY) | — | -100.0% |
| Revenue CAGR (multi-year) | +2.9% | +17.9% |
| Financial health | ||
| Debt to equity | 0.00 | 0.16 |
| Momentum | ||
| 1-month return | +5.4% | +13.6% |
| 1-year return | +0.5% | +16.4% |
| 3-year CAGR | +22.0% | +16.9% |
| 5-year CAGR | +10.1% | — |
| 10-year CAGR | +7.2% | — |
| Distance from 52W high | -14.0% | -3.6% |
| Technicals | ||
| RSI (14) | 72 | 88 |
| Price vs 200-day avg | +5.9% | +15.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glaxosmithkline Pharmaceuticals | Global Health |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 7/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glaxosmithkline Pharmaceuticals or Global Health?
Glaxosmithkline Pharmaceuticals has a market cap of ₹45,277 Cr and Global Health has a market cap of ₹39,065 Cr as of 13 Nov 2026.
Which has a lower P/E, Glaxosmithkline Pharmaceuticals or Global Health?
Glaxosmithkline Pharmaceuticals has the lower P/E: Glaxosmithkline Pharmaceuticals trades at 87.9 and Global Health at 98.2.
Which gave better returns in the last year, Glaxosmithkline Pharmaceuticals or Global Health?
Global Health did better: Glaxosmithkline Pharmaceuticals returned +0.5% and Global Health returned +16.4% over one year.
What is the difference between Glaxosmithkline Pharmaceuticals and Global Health?
Both are NSE-listed companies in Healthcare. Glaxosmithkline Pharmaceuticals is about 1.2 times the size of Global Health by market cap. In the latest financial year Glaxosmithkline Pharmaceuticals reported revenue of ₹3,822 Cr and Global Health ₹4,410 Cr. Operating margin is 34.1% for Glaxosmithkline Pharmaceuticals and 22.1% for Global Health. Debt to equity is 0.00 for Glaxosmithkline Pharmaceuticals and 0.16 for Global Health.
Which is better, Glaxosmithkline Pharmaceuticals or Global Health?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Glaxosmithkline Pharmaceuticals leads on 7 and Global Health on 7. Glaxosmithkline Pharmaceuticals is ahead on size, valuation and profitability. Global Health is ahead on growth, momentum and technicals. On StoxGud's rules-based checklist Glaxosmithkline Pharmaceuticals scores 7/10 and Global Health scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.